Efficacy of a high potency O1Manisa foot-and-mouth disease vaccine in cattle against heterologous challenge with a field virus from the O/ME-SA/Ind-2001 lineage collected in North Africa
Outbreaks of foot-and-mouth disease (FMD) in North Africa (2013) and the Gulf States (2013) of the Middle East have been caused by a FMD viral lineage (O/ME-SA/Ind-2001) that was before 2013 restricted to the Indian Sub-continent. This study was undertaken to assess thein vivoefficacy of a FMD virus emergency vaccine type O1Manisa against heterologous challenge with a representative field virus (O/ALG/3/2014) from this emerging lineage. This widely available vaccine was selected sincein vitrovaccine-matching results gave inconclusive results as to whether or not it would be protective. Three groups of five cattle were vaccinated with O1Manisa (homologous potency >=6PD50/dose) using study guidelines outlined in the European Pharmacopeia, and challenged at 21days post-vaccination by tongue inoculation. All animals that were vaccinated with the lowest dose (1/16) of vaccine developed generalised FMD, defined as vesicular lesions at the feet. One animal vaccinated with a 1/4 dose of the vaccine also developed generalised disease, as did two animals vaccinated with the full dose of vaccine. These results indicate that the heterologous potency of this high potency O1Manisa vaccine was approximately 3.5 PD50/dose. These data support the use of the O1Manisa vaccine for FMD control in areas where FMDV is endemic e.g. North Africa, and motivate further studies to evaluate other vaccine candidates (or multivalent combinations) that might be potentially used for emergency purposes in FMD-free settings..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Vaccine - 35(2017), 20, Seite 2761 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Emma Fishbourne [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Animals |
|---|
| doi: |
10.1016/j.vaccine.2017.02.047 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1994913533 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1994913533 | ||
| 003 | DE-627 | ||
| 005 | 20230715055601.0 | ||
| 007 | tu | ||
| 008 | 170721s2017 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.vaccine.2017.02.047 |2 doi | |
| 028 | 5 | 2 | |a PQ20170901 |
| 035 | |a (DE-627)OLC1994913533 | ||
| 035 | |a (DE-599)GBVOLC1994913533 | ||
| 035 | |a (PRQ)p572-11655d84fbc32ae0d2507c0079c76e41a4b9a94692e316b9156d3d8bcf1381910 | ||
| 035 | |a (KEY)0128923320170000035002002761efficacyofahighpotencyo1manisafootandmouthdiseasev | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 100 | 0 | |a Emma Fishbourne |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy of a high potency O1Manisa foot-and-mouth disease vaccine in cattle against heterologous challenge with a field virus from the O/ME-SA/Ind-2001 lineage collected in North Africa |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Outbreaks of foot-and-mouth disease (FMD) in North Africa (2013) and the Gulf States (2013) of the Middle East have been caused by a FMD viral lineage (O/ME-SA/Ind-2001) that was before 2013 restricted to the Indian Sub-continent. This study was undertaken to assess thein vivoefficacy of a FMD virus emergency vaccine type O1Manisa against heterologous challenge with a representative field virus (O/ALG/3/2014) from this emerging lineage. This widely available vaccine was selected sincein vitrovaccine-matching results gave inconclusive results as to whether or not it would be protective. Three groups of five cattle were vaccinated with O1Manisa (homologous potency >=6PD50/dose) using study guidelines outlined in the European Pharmacopeia, and challenged at 21days post-vaccination by tongue inoculation. All animals that were vaccinated with the lowest dose (1/16) of vaccine developed generalised FMD, defined as vesicular lesions at the feet. One animal vaccinated with a 1/4 dose of the vaccine also developed generalised disease, as did two animals vaccinated with the full dose of vaccine. These results indicate that the heterologous potency of this high potency O1Manisa vaccine was approximately 3.5 PD50/dose. These data support the use of the O1Manisa vaccine for FMD control in areas where FMDV is endemic e.g. North Africa, and motivate further studies to evaluate other vaccine candidates (or multivalent combinations) that might be potentially used for emergency purposes in FMD-free settings. | ||
| 650 | 4 | |a Animals | |
| 650 | 4 | |a Epidemics | |
| 650 | 4 | |a Pharmacology | |
| 650 | 4 | |a Viruses | |
| 650 | 4 | |a Foot & mouth disease | |
| 650 | 4 | |a Vaccination | |
| 650 | 4 | |a Immunization | |
| 650 | 4 | |a Foot-and-mouth disease | |
| 650 | 4 | |a Cattle | |
| 650 | 4 | |a Feet | |
| 650 | 4 | |a Homology | |
| 650 | 4 | |a Foot | |
| 650 | 4 | |a Inoculation | |
| 650 | 4 | |a Lesions | |
| 650 | 4 | |a Tongue | |
| 650 | 4 | |a Outbreaks | |
| 650 | 4 | |a Vaccines | |
| 700 | 0 | |a Anna B Ludi |4 oth | |
| 700 | 0 | |a Ginette Wilsden |4 oth | |
| 700 | 0 | |a Pip Hamblin |4 oth | |
| 700 | 0 | |a Bob Statham |4 oth | |
| 700 | 0 | |a Abdelghani Bin-Tarif |4 oth | |
| 700 | 0 | |a Emiliana Brocchi |4 oth | |
| 700 | 0 | |a Santina Grazioli |4 oth | |
| 700 | 0 | |a Aldo Dekker |4 oth | |
| 700 | 0 | |a Phaedra Eblé |4 oth | |
| 700 | 0 | |a Donald P King |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccine |d Amsterdam : Elsevier, 1983 |g 35(2017), 20, Seite 2761 |w (DE-627)130402427 |w (DE-600)605674-X |w (DE-576)015904938 |x 0264-410X |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2017 |g number:20 |g pages:2761 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1016/j.vaccine.2017.02.047 |3 Volltext |
| 856 | 4 | 2 | |u https://search.proquest.com/docview/1890235622 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_4219 | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2017 |e 20 |h 2761 | ||